Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:IMA NASDAQ:INMB NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.58-6.5%$1.63$1.03▼$2.41$49.29M-0.3400,341 shs390,884 shsIMAImageneBio$7.96-5.8%$15.00$7.95▼$23.28$33.97M0.4925,319 shs181,260 shsINMBINmune Bio$1.95+1.6%$2.41$1.86▼$11.64$51.04M1.03766,853 shs795,664 shsPRPHProPhase Labs$0.35-0.4%$0.37$0.22▼$3.00$14.81M-0.7815.46 million shs1.21 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-6.51%-11.24%-1.25%-13.66%-12.22%IMAImageneBio-5.80%-40.60%-49.46%-53.29%-60.28%INMBINmune Bio+1.56%-3.94%-29.35%-74.41%-68.29%PRPHProPhase Labs-0.42%+4.97%+12.13%-0.87%-86.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.58-6.5%$1.63$1.03▼$2.41$49.29M-0.3400,341 shs390,884 shsIMAImageneBio$7.96-5.8%$15.00$7.95▼$23.28$33.97M0.4925,319 shs181,260 shsINMBINmune Bio$1.95+1.6%$2.41$1.86▼$11.64$51.04M1.03766,853 shs795,664 shsPRPHProPhase Labs$0.35-0.4%$0.37$0.22▼$3.00$14.81M-0.7815.46 million shs1.21 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-6.51%-11.24%-1.25%-13.66%-12.22%IMAImageneBio-5.80%-40.60%-49.46%-53.29%-60.28%INMBINmune Bio+1.56%-3.94%-29.35%-74.41%-68.29%PRPHProPhase Labs-0.42%+4.97%+12.13%-0.87%-86.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50184.81% UpsideIMAImageneBio 2.50Moderate Buy$35.50345.98% UpsideINMBINmune Bio 2.57Moderate Buy$18.40843.59% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRPH, ATNM, INMB, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$25.00 ➝ $23.007/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AIMAImageneBio$9.16M3.49N/AN/A$31.33 per share0.25INMBINmune Bio$10K5,183.10N/AN/A$1.45 per share1.34PRPHProPhase Labs$5.59M2.64N/AN/A$0.25 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AIMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)Latest PRPH, ATNM, INMB, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 million8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25IMAImageneBioN/A13.5213.52INMBINmune BioN/A4.204.20PRPHProPhase Labs0.200.960.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%IMAImageneBio75.00%INMBINmune Bio12.72%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%IMAImageneBio5.94%INMBINmune Bio35.70%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableIMAImageneBio704.02 million3.78 millionNot OptionableINMBINmune Bio1026.58 million17.09 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionablePRPH, ATNM, INMB, and IMA HeadlinesRecent News About These CompaniesProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3 at 6:34 PM | markets.businessinsider.comProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3 at 8:00 AM | globenewswire.comProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comProPhase Labs files definitive proxy statement for special meetingAugust 20, 2025 | msn.comProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersAugust 19, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future ProspectsAugust 15, 2025 | finance.yahoo.comProPhase Labs Reports Turnaround and Strategic GrowthAugust 14, 2025 | msn.comProPhase Labs Posts Narrower Q2 LossAugust 13, 2025 | aol.comAProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025August 13, 2025 | globenewswire.comProPhase Labs stock soars after securing patent for esophageal disease testAugust 12, 2025 | investing.comEarnings Preview For ProPhase LabsAugust 12, 2025 | benzinga.comProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease TestAugust 12, 2025 | msn.comWhy Is ProPhase Labs Stock (PRPH) Up 25% Today?August 12, 2025 | msn.comProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk AssessmentAugust 12, 2025 | globenewswire.comProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025August 11, 2025 | globenewswire.comProPhase Labs Appoints New Fractional CFOAugust 6, 2025 | tipranks.comProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy StatementJuly 29, 2025 | globenewswire.comProPhase Labs announces closing of $3M senior secured convertible notesJuly 25, 2025 | msn.comProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes FinancingJuly 23, 2025 | globenewswire.comProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury InitiativeJuly 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, ATNM, INMB, and IMA Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.58 -0.11 (-6.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.55 -0.03 (-1.90%) As of 09/5/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.ImageneBio NASDAQ:IMA$7.96 -0.49 (-5.80%) As of 09/5/2025 04:00 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.INmune Bio NASDAQ:INMB$1.95 +0.03 (+1.56%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.77%) As of 09/5/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.ProPhase Labs NASDAQ:PRPH$0.35 0.00 (-0.42%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.35 0.00 (-0.54%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
